Visceral fat measured with CT helps predict recurrence-free survival in patients with localized clear cell renal cell carcinoma
- PMID: 40699413
- DOI: 10.1007/s11255-025-04681-1
Visceral fat measured with CT helps predict recurrence-free survival in patients with localized clear cell renal cell carcinoma
Abstract
Background: To investigate the prognostic significance of visceral fat to predict recurrence-free survival in patients with localized clear cell renal cell carcinoma (ccRCC).
Methods: This study included patients with localized ccRCC who had undergone curative surgery. Visceral, subcutaneous fat and the relative visceral fat area (rVFA) were quantified utilizing preoperative CT images. The association between rVFA and recurrence-free survival (RFS) was explored using restricted cubic splines, Cox proportional hazards regression, and Kaplan-Meier survival analysis. The predictive capability of rVFA was evaluated using the Boruta algorithm, a predictive model was developed using the random survival forest (RSF) with results visualized via Shapley additive explanations (SHAP).
Results: Four hundred and forty six patients were included. The follow-up median duration was 48.5 months, during which 57 patients experienced metastasis or death. Restricted cubic spline model revealed a nonlinear association between rVFA and tumor progression, exhibiting a U-shaped curve trend with an inflection point at 0.40. Beyond this threshold, rVFA was significantly correlated with an increased risk of progression. The RSF model yielded an area under the curve (AUC) of 0.89 for predicting 1-year RFS, 0.73 for 3-year RFS, and 0.75 for 5-year RFS. Both Boruta and SHAP analyses identified rVFA as a significant predictive feature.
Conclusions: A U-shaped association between rVFA and risk of tumor recurrence was observed among patients with ccRCC. A high rVFA is significantly correlated with an increased risk of adverse events, thus indicating that rVFA is a potential indicator for predicting the prognosis of ccRCC.
Keywords: Clear cell renal cell carcinoma (ccRCC); Recurrence-free survival (RFS); Relative visceral fat area (rVFA).
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethical approval: The study was approved by the Scientific research IRB of the XXX and the requirement for informed consent was waived. Conflict of interests: The authors declare no competing interests.
Similar articles
-
Are Current Survival Prediction Tools Useful When Treating Subsequent Skeletal-related Events From Bone Metastases?Clin Orthop Relat Res. 2024 Sep 1;482(9):1710-1721. doi: 10.1097/CORR.0000000000003030. Epub 2024 Mar 22. Clin Orthop Relat Res. 2024. PMID: 38517402
-
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23. Clin Orthop Relat Res. 2024. PMID: 39051924
-
Does the Presence of Missing Data Affect the Performance of the SORG Machine-learning Algorithm for Patients With Spinal Metastasis? Development of an Internet Application Algorithm.Clin Orthop Relat Res. 2024 Jan 1;482(1):143-157. doi: 10.1097/CORR.0000000000002706. Epub 2023 Jun 12. Clin Orthop Relat Res. 2024. PMID: 37306629 Free PMC article.
-
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2. Cochrane Database Syst Rev. 2022. PMID: 36161421 Free PMC article.
-
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2. Cochrane Database Syst Rev. 2021. PMID: 34515338 Free PMC article.
References
-
- Ljungberg B, Albiges L, Abu-Ghanem Y, Bedke J, Capitanio U, Dabestani S et al (2022) European Association of Urology guidelines on renal cell carcinoma: the 2022 update. Eur Urol 82(4):399–410 - PubMed
-
- Bedke J, Albiges L, Capitanio U, Giles RH, Hora M, Ljungberg B et al (2023) The 2022 updated European association of urology guidelines on the use of adjuvant immune checkpoint inhibitor therapy for renal cell carcinoma. Eur Urol 83(1):10–14 - PubMed
-
- Vrieling A, Kampman E, Knijnenburg NC, Mulders PF, Sedelaar JPM, Baracos VE et al (2018) Body composition in relation to clinical outcomes in renal cell cancer: a systematic review and meta-analysis. Eur Urol Focus 4(3):420–434 - PubMed
-
- Turco F, Tucci M, Di Stefano RF, Samuelly A, Bungaro M, Audisio M et al (2021) Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC. Endocr Relat Cancer 28(7):R207–R216 - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources